Awaiting product image

Ihc – Breast Cancer Prognosis Profile # 4a (Er, Pr, Her2neu Gene Amplification, Egfr Overexpression)

₹27,000.00

15 minutes
Categories: ,

This panel of tests uses Immunohistochemistry (IHC) and In Situ Hybridization (ISH/FISH) techniques to analyze breast cancer tissue samples for the presence and activity of key receptors and gene alterations:

• ER (Estrogen Receptor): Determines if the cancer cells grow in response to estrogen.
• PR (Progesterone Receptor): Evaluates whether the cancer is influenced by progesterone.
• HER2neu Gene Amplification: Assesses if there are extra copies of the HER2 gene, which can promote aggressive tumor growth.
• EGFR (Epidermal Growth Factor Receptor) Overexpression: Checks if the EGFR protein is overly expressed, which can affect treatment decisions and prognosis.
These biomarkers help oncologists classify the type of breast cancer and guide targeted therapy decisions.

Enquiry Here

    Description

    Why It’s Done:

    This test is critical for:
    • Diagnosing the type and subtype of breast cancer.
    • Determining hormone receptor status, which affects the choice of hormonal therapies.
    • Evaluating HER2 status, which helps in deciding on anti-HER2 targeted therapies (like trastuzumab).
    • Assessing EGFR overexpression, which may influence prognosis and emerging treatment options.
    By understanding these markers, doctors can better predict how aggressive the cancer is, whether it will respond to certain treatments, and the likely outcomes (prognosis).

    Preparation:

    • No special preparation is required for the patient.
    • The test is performed on a tissue sample obtained through biopsy or surgery.
    • If you’re undergoing a biopsy or surgery, your healthcare provider will give you specific pre-procedure instructions (e.g., fasting, medication adjustments).
    • Make sure to inform your doctor about any current medications, medical conditions, or prior cancer treatments.

    Related products